James Fletcher
Family Medicine · Arlington, WANPI 1407935091
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 151 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 18.2% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $796 and has fallen 97.5% since, to $20 in 2025. Among family medicine clinicians in WA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 151 payments — averaging $20.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$554
- Lilly USA, LLC$306
- Boehringer Ingelheim$264
- Novo Nordisk$254
- AbbVie$223
- Johnson & Johnson$173
- plus $1K from 30 others
What the payments were for
- Food & beverage$3,02099%
- Education$201%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 33 | $554 |
| Lilly USA, LLC | 14 | $306 |
| Boehringer Ingelheim | 13 | $264 |
| Novo Nordisk | 10 | $254 |
| AbbVie(2 entities) | 11 | $223 |
| Johnson & Johnson | 8 | $173 |
| GSK | 6 | $103 |
| Biohaven Pharmaceuticals, Inc. | 2 | $83 |
| Teva Pharmaceuticals USA, Inc. | 4 | $81 |
| E.r. Squibb & Sons, L.L.C. | 4 | $76 |
| Abbott | 3 | $76 |
| Pfizer | 4 | $69 |
| Sanofi-aventis U.S. LLC | 3 | $65 |
| Merck | 4 | $65 |
| Amgen | 3 | $52 |
| Boston Scientific | 2 | $51 |
| Novartis | 2 | $46 |
| Sanofi Pasteur Inc. | 2 | $43 |
| Eisai Inc. | 2 | $42 |
| Jazz Pharmaceuticals Inc. | 2 | $39 |
| Amarin Pharma, Inc. | 2 | $37 |
| Antares Pharma, Inc. | 2 | $36 |
| Bayer | 2 | $30 |
| Astellas Pharma US Inc | 1 | $24 |
| Bausch Health US, LLC | 1 | $24 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $23 |
| Shire North American Group Inc | 1 | $23 |
| Neurelis, Inc. | 1 | $23 |
| Mylan Specialty L.p. | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $22 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $21 |
| Collegium Pharmaceutical, Inc. | 1 | $21 |
| Axsome Therapeutics, Inc. | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Circassia Inc. | 1 | $12 |
How this compares
$3,040 in reported general payments places this provider in the 90th percentile of 2,275 family medicine providers in Washington.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $15,080 |
| Atorvastatin Calcium | 47 | $632 |
| Lisinopril | 37 | $300 |
| Metoprolol Succinate | 18 | $268 |
| Losartan Potassium | 24 | $247 |
| Omeprazole | 22 | $246 |
| Simvastatin | 14 | $190 |
| Pravastatin Sodium | 13 | $172 |
| Sertraline Hcl | 15 | $151 |
| Metformin Hcl | 20 | $131 |
| Finasteride | 11 | $109 |
| Levothyroxine Sodium | 14 | $98 |
| Amlodipine Besylate | 15 | $95 |
| Trazodone Hcl | 13 | $85 |
| Hydrochlorothiazide | 17 | $58 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $69 | $15,08018 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,275 family medicine providers in Washington.
Other family medicine in Arlington
- Kevin HatfieldSeattle$527K
- Marta KazymyraBlaine$222K
- Donella YoungDavenport$175K
- Robert McIntyreSeattle$107K
- James MorenBellingham$106K
- Marshall BrownPasco$70K
- Cynthia CoteMaple Valley$66K
- Greg LedgerwoodBrewster$66K
- Daniel RivasBurien$50K
- Kent WalkerSumner$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.